Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties. To address this overlooked aspect of pharmacology, we aim to (i), highlight how physical stimuli (mechanical, optical, magnetic, electrical) influence inflammation; (ii) identify known overlaps among transduction mechanisms of physical stimuli and highlight the need for deeper understanding of these mechanisms; (iii) promote advanced network approaches as tools to understand this complexity and enhance the potential of anti-inflammatory physical therapies; and (iv), integrate physical stimuli into the mindset of pharmacologists. The overall purpose of this review is to spark questions rather than provide answers, and to drive research in this critically underexplored area.

Electrostimulation is the object of the study of a variety of clinical approaches, ranging from bioelectronic medicine where the aim is to elicit the activity of the autonomic nervous system (ANS), to electroacupuncture with the general objective to restore homeostasis, to transcutaneous electrical nerve stimulation (TENS) to control pain and degeneration, to name a few. Among the numerous obstacles preventing from a clear adoption or rejection of these approaches in mainstream clinical practice, is the difficulty in standardizing experimental systems for testing and validation. Consequently, indications on the appropriate magnitude of an effective stimulus (duration, frequency, intensity) remain unclear. To approach this issue we present preliminary results on the differential molecular activity elicited in a 3D bioprinted construct containing fibroblasts and keratinocytes in a collagen matrix, by two diverse types of electrical stimulation (direct and alternate current). Two conditions, physiology and inflammation induced by TNF? perfusion were tested with anelectrobiomedical device. The system mimics a simplified model of skin, the largest and most accessible of our organs, in inflamed or physiological states, treated by electrostimulation. The bioprinted sample is constructed to yield an appropriate number of cell enabling high-throughput screens. We report here our preliminary results on RNA-seq differential expression comparing direct and alternate current stimuli, with a focus on wound healing and inflammation as part of the greater inflammatory pathway. Our construct offer reproducibility of the experience, and direct comparison among potentially numerous conditions and types of stimulation. Our preliminary results shows that electrostimulation offers differential elicitation of biological functions. In particular, direct and alternate current provoke differential activation of proliferation and development associated functions.

Motivation Inflammation is part of the complex function that addresses harmful stimuli, and the first phase of wound healing (WH), which guarantees living systems' homeostasis. Deviances from physiology make inflammation turn acute (sepsis, 11M death/y) or chronic (non-communicable diseases, 41M death/y). Therefore, tackling inflammation is a key priority. We recently proposed (Maturo et al., 2020) to revise the conventional inflammatory pathway (innate immune response) to include WH (expanded inflammatory pathway). Methods We manually identified the Reactome pathways that include all reactions and species relevant to WH. Cytoscape was then used to perform the union of the SBML converted pathways, with the largest connected component being retained (732 nodes, 13.944 edges). The same was done for the innate immune response (R-HSA-168249.8) with 487 nodes, 11.744 edges. We then focused on: NF-kB (fundamental hub in all inflammatory reactions), TNF-? (renown target of inflammatory diseases) and RAC1 (key player in mechanotransduction events of WH). Results Preliminary topological results highlight the stability of closeness centrality, i.e. all molecules preserve their efficiency in spreading information. Conversely, betweenness centrality is stable for NF-kB (0.068), confirming NF-kB relevance, while halving its (very low) value in the expanded pathway for TNF-? (from 2.85E-06 to 1.29E-06). This indicates that the ability to bridge different parts of the graphs is less effective if we consider inflammation as an expanded concept, possibly contributing to explain the many side effects of anti-TNF-? therapies. Interestingly, RAC1 presents stable betweenness (from 0.094 to 0.093), comparable to NF-kB, supporting the hypothesis that WH-leveraging therapies could act on a relevant and stable target, so far neglected (Nardini et al., 2016).

The ongoing COVID-19 pandemic still requires fast and effective efforts from all fronts, including epidemiology, clinical practice, molecular medicine, and pharmacology. A comprehensive molecular framework of the disease is needed to better understand its pathological mechanisms, and to design successful treatments able to slow down and stop the impressive pace of the outbreak and harsh clinical symptomatology, possibly via the use of readily available, off-the-shelf drugs. This work engages in providing a wider picture of the human molecular landscape of the SARS-CoV-2 infection via a network medicine approach as the ground for a drug repurposing strategy. Grounding on prior knowledge such as experimentally validated host proteins known to be viral interactors, tissue-specific gene expression data, and using network analysis techniques such as network propagation and connectivity significance, the host molecular reaction network to the viral invasion is explored and exploited to infer and prioritize candidate target genes, and finally to propose drugs to be repurposed for the treatment of COVID-19. Ranks of potential target genes have been obtained for coherent groups of tissues/organs, potential and distinct sites of interaction between the virus and the organism. The normalization and the aggregation of the different scores allowed to define a preliminary, restricted list of genes candidates as pharmacological targets for drug repurposing, with the aim of contrasting different phases of the virus infection and viral replication cycle.

L'idea imprenditoriale da cui prende origine la start-up ProNeuro, nasce come conseguenza del lavoro di ricerca svolto dai soci fondatori presso il Consiglio Nazionale delle Ricerche (CNR). Questo lavoro ha portato negli ultimi 3 anni al deposito di due domande di brevetto italiano, di cui una già estesa in PCT, che proteggono l'utilizzo della molecola ProNGF-A per scopi terapeutici mirati alla cura di patologie neurologiche e infiammatorie (domanda di brevetto Nr. 102018000003279 del 05/03/2018 e PCT/IB2019/051753 del 05/03/2019) e la produzione di una forma mutata di ProNGF-A e il suo utilizzo per terapia neurologica e di patologie cutanee (domanda di brevetto numero 102019000014646 del 12/08/2019). Tali brevetti sono di proprietà del CNR, mentre ProNeuro ha messo a punto un sistema di offerta finalizzato alla loro valorizzazione. Attraverso attività di Ricerca e Sviluppo, ProNeuro individua principi attivi farmacologici con attività protettiva e riparativa per il sistema nervoso, ne modifica la struttura per renderli maggiormente efficaci, sicuri e biocompatibili, mette a punto i metodi produttivi ed esegue le prime fasi di caratterizzazione dei loro effetti, prima di proporli ad aziende farmaceutiche per un successivo sviluppo come farmaci destinati al mercato. ProNeuro commercializza, quindi, i diritti di utilizzo della proprietà intellettuale e una serie di prodotti collegati alle attività di discovery, produzione (trasferimento tecnologico) e prima validazione sia predittiva che biologica di nuovi neurofarmaci. ProNeuro avrà la forma giuridica di Società a responsabilità limitata e si configura come spin-off CNR. Come tale, il rapporto tra la società ProNeuro e il CNR è regolato dal "Regolamento per la costituzione e la partecipazione del CNR alle Imprese Spin off, Del,18/2019". I brevetti sopracitati, attualmente di proprietà del CNR, verranno concessi in licenza a ProNeuro, con possibilità di sub-licenziare a terzi, sulla base del suddetto Regolamento. Questo prevede, infatti, la cessione a condizioni agevolate delle licenze sui brevetti di proprietà CNR, la messa a disposizione di risorse logistiche e strumentali in fase di start-up e l'autorizzazione al proprio personale a svolgere attività a favore delle spin-off, con copertura dei costi salariali per un terzo del tempo lavorativo per tre anni. La sede dell'impresa è stata individuata presso l'Istituto di Farmacologia Traslazionale del CNR, via del Fosso del Cavaliere 100, 00133 Roma

Background and limitations Impaired wound healing (WH) and chronic inflammation are hallmarks of non-communicable diseases (NCDs). However, despite WH being a recognized player in NCDs, mainstream therapies focus on (un)targeted damping of the inflammatory response, leaving WH largely unaddressed, owing to three main factors. The first is the complexity of the pathway that links inflammation and wound healing; the second is the dual nature, local and systemic, of WH; and the third is the limited acknowledgement of genetic and contingent causes that disrupt physiologic progression of WH. Proposed approach Here, in the frame of Predictive, Preventive, and Personalized Medicine (PPPM), we integrate and revisit current literature to offer a novel systemic view on the cues that can impact on the fate (acute or chronic inflammation) of WH, beyond the compartmentalization of medical disciplines and with the support of advanced computational biology. Conclusions This shall open to a broader understanding of the causes for WH going awry, offering new operational criteria for patients' stratification (prediction and personalization). While this may also offer improved options for targeted prevention, we will envisage new therapeutic strategies to reboot and/or boost WH, to enable its progression across its physiological phases, the first of which is a transient acute inflammatory response versus the chronic low-grade inflammation characteristic of NCDs.